Case study: Skin Analytics
Skin Analytics specialises in screening for melanoma and non-melanoma skin cancers. The company invested heavily in technology with the potential to disrupt the process of diagnosis and management of skin cancer, and has validated their proprietary AI in two large studies.
Having just won the UKBAA Best AI Investment 2018 and Advance Queensland Ignite Grant in 2018 and received several other awards, grants and accolades, Skin Analytics is on the right path to expanding further into the UK, Australia and New Zealand private and public healthcare markets.
The company has now already entered into primary care agreements as well as commercial contracts with private medical insurers and providers.
Skin Analytics raised £1.6m funding in this round, from RYSE and other investors, to finalise the first prospective clinical study in applying AI to dermatology, secure the regulatory approval, and bring on the high calibre team needed to deploy the technology into a variety of patient pathways.
“Working with RYSE and DH.L has given us great access to leading NHS initiatives and those behind them as well as the financial support needed to get our technology to the point it will positively impact patients and the healthcare service."
Neil Daly, CEO Skin Analytics
Case study: LiveSmart
LiveSmart provides pathology-based health assessments, digital health data tracking, reporting and behaviour change programmes, alongside one-to-one health coaching services led by their medical team.
Through the RYSE Early Stage Investment Programme, entrepreneurs are able to access the information they need to raise grants or private funding successfully at each stage of their development.In addition to funding opportunities, LiveSmart were keen to participate in the RYSE Early Stage Investment Programme to gain the further technological validation of their product through the panel of DH.L reviewers.
The company's development focus is to form commercial partnerships with health insurers and other intermediaries. Its most recent partnership has provided LiveSmart a stamp of pre-approval and global access to over 100 million of their customers.
LiveSmart raised £1.25m funding in this round to expand sales into other geographical jurisdictions, securing additional long-term partnerships with other substantial players in the insurance market and improving tech.
“Navigating the digital health landscape is complex. Choosing to work with specialists like RYSE and DH.L was a no brainer for us. Their deep knowledge and understanding of the health and funding environment will continue to be a major advantage for us moving forward.”
Alex Heaton, CEO LiveSmart